Lung cancer company LUNGevity Foundation disclosed on Monday the promotion of Upal Basu Roy, PhD, MPH to vice president of its Research.
In the elevated position, Dr Basu Roy will manage the company's extensive educational library as well as lead the Translational Research programme, the Career Development Award programme, the research funded through the ALK Positive partnership and the Patient Focused Research Center – Patient FoRCe.
Previously, Dr Basu Roy led community-based participatory research (CBPR) methodology in health sciences research, projects involving immigrants and minority populations,led diabetes education for Asian immigrants in New York City as well as educated minority populations about breast cancer screening in Queens, NY.
The company added that Dr Basu Roy has a PhD in Molecular and Cellular Biology from the University of Arizona and an MPH in Global Health Policy and Management from New York University.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib